SCY-078 (MK-3118)

Title Content type
A prospective, phase 2, multicentre, open-label, randomized, comparative study to estimate the safety, tolerability, pharmacokinetics, and efficacy of oral SCY-078 vsstandard-of-care following initial intravenous echinocandin therapy in the treatment of.. (click for details)
Evaluation of the antifungal activity of SCY-078 in combination with other antifungals against Aspergillus strains (click for details)
A prospective, phase 2, multicentre, open-label, randomized, comparative study to estimate the safety, tolerability, pharmacokinetics, and efficacy of oral SCY-078 vsstandard-of-care following initial intravenous echinocandin therapy in the treatment of.. (click for details)
Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis. (click for details)
Scynexis (SCYX) Announces Results from Two Completed SCY-078 Phase 2s; Closes $15 Term Loan (click for details)
Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis (click for details)
SCYNEXIS, Inc. Receives Orphan Drug Designation For SCY-078 For The Treatment Of Invasive Candida Infections (click for details)
Scynexis' (SCYX) SCY-078 Receives FDA Fast Track and QIDP Designations (click for details)
Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. (click for details)
SCYNEXIS starts phase 1 study to evaluate intravenous formulation of SCY-078 (click for details)

Pages

Subscribe to SCY-078 (MK-3118)